Remdesivir efficacy against yellow fever in a hamster model

Antiviral Res. 2022 Jul:203:105331. doi: 10.1016/j.antiviral.2022.105331. Epub 2022 May 6.

Abstract

Yellow fever virus (YFV) continues to cause periodic outbreaks of severe disease throughout tropical regions of South America and Africa despite the availability of an effective vaccine. Despite efforts to control this virus for the last century, no antivirals have been approved for the treatment of YFV. The purpose of this study was to evaluate the broadly active antiviral compound remdesivir (RDV) in a hamster model of disease. Yellow fever (YF) disease in hamsters was prevented when treatment with RDV was initiated just prior to virus challenge, which was confirmed in a second study. Disease parameters including viremia, serum ALT and weight loss were significantly improved with RDV treatment in a dose-dependent manner. RDV was also effective when treatment was initiated as late as 4 days post-virus infection (dpi). These results demonstrate therapeutic efficacy of RDV in the treatment of YF in a relevant animal model of disease.

Keywords: Antiviral; Hamster; In vivo; Nucleotide prodrug; Remdesivir; Yellow fever.

Publication types

  • Research Support, N.I.H., Extramural

MeSH terms

  • Adenosine Monophosphate / analogs & derivatives
  • Alanine / analogs & derivatives
  • Animals
  • Antiviral Agents / therapeutic use
  • Cricetinae
  • Viremia / drug therapy
  • Yellow Fever Vaccine* / therapeutic use
  • Yellow Fever* / prevention & control
  • Yellow fever virus

Substances

  • Antiviral Agents
  • Yellow Fever Vaccine
  • remdesivir
  • Adenosine Monophosphate
  • Alanine